First Autonomous Blood-Draw Robot Wins FDA Clearance for U.S. Use
Dutch medical robotics firm Vitestro has secured U.S. Food and Drug Administration authorization for Aletta, the first autonomous blood-draw device approved for clinical use in the United States. The clearance, granted on August 19, applies to adults in non-hospitalized settings and follows European regulatory approval two years earlier.
The Aletta system automates the entire phlebotomy workflow using a combination of imaging and robotic technologies. The process begins with near-infrared light scanning the inner elbow to locate veins, followed by ultrasound imaging to map vessel depth and curvature. Doppler technology determines blood flow direction to distinguish veins from arteries. Once targeting is complete, a cuff tightens around the upper arm, and a needle precisely inserts and withdraws blood into collection tubes that rotate end-over-end nine times each for consistent mixing.
The device represents a notable engineering achievement in autonomous medical robotics. Healthcare robotics specialists have noted the sophisticated integration of multiple imaging modalities and precision motion control required to perform a task that human phlebotomists accomplish through tactile feedback and experience.
Vitestro's entry into the U.S. market follows a growing trend toward automation in clinical settings, where consistent, repeatable procedures may help address workflow demands and reduce variability in specimen collection quality.